華潤啤酒(00291.HK)訂立2019年框架貸款協議
格隆匯12月17日丨華潤啤酒(00291.HK)發佈公告,有關訂立2013年框架貸款協議及2016年框架貸款協議。由於2016年框架貸款協議將於2019年12月31日屆滿,故公司已訂立新貸款安排,據此經考慮公司的經營規模及現金水平後更新年度上限。
公告表示,2019年框架貸款協議為公司管理其現金盈餘資源提供更大靈活性,使公司可將其及其附屬公司的部分現金盈餘資源借予包括華潤股份及華潤集團公司在內的其他華潤集團旗下公司。集團於任何單日可借出的最高總金額的年度貸款上限乃經評估集團在其估計暫時現金盈餘資源情況下根據2019年框架貸款協議隨時準備承擔的最高風險金額以及該公告所載集團借出的過往金額後釐定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.